

Participants may receive up to 3 Category 1 credits toward the American Medical Association Physician's Recognition Award by reading the material in this Supplement and correctly answering at least 70% of the questions in the Posttest that follows.

Go to www.psychiatrist.com/cmehome to take this Posttest online and earn credit immediately.

Or

1. Read each question carefully and circle the answer on the Registration Form.
2. Type or print the registration information in the spaces provided and complete the evaluation.
3. Send the Registration Form to the address or fax number listed on the Registration Form.

All replies and results are confidential. Answer sheets, once graded, will not be returned. Unanswered questions will be considered incorrect and so scored. The CME Institute of Physicians Postgraduate Press, Inc. will keep only a record of participation, which indicates the completion of the activity and the designated number of Category 1 credits that have been awarded. Correct answers to the Posttest will be made available to the participants of this activity upon request after the submission deadline.

Accreditation Statement

Physicians Postgraduate Press, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

1. According to Manning, mirtazapine:

- a. Is a pure selective serotonin reuptake inhibitor
- b. Has not been found to be as efficacious as tricyclic antidepressants
- c. May have a faster onset of action than paroxetine
- d. Has not been associated with weight gain or sedation

2. According to Manning, escitalopram:

- a. Was developed to provide superior efficacy and tolerability over citalopram
- b. Enhances both serotonergic and noradrenergic neurotransmission
- c. Has high rates of dry mouth and sedation
- d. Is associated with less nausea than placebo

3. According to Manning, duloxetine:

- a. Enhances both serotonergic and noradrenergic neurotransmission but not by inhibiting their reuptake
- b. Is more effective after titration up from the starting dose of 60 mg/day
- c. Is associated with mild-to-moderate and transient nausea, but discontinuation due to adverse events was not statistically different from that of placebo
- d. Is less effective for pain than antidepressants with single monoamine activity

4. According to Jain, the dual-action serotonin and norepinephrine antidepressants include the investigational medication duloxetine and all of the following *except*:

- a. Sertraline
- b. Venlafaxine
- c. Amitriptyline
- d. Mirtazapine

5. According to Jain, the new dual-action antidepressants may provide a faster speed of onset and higher rates of remission than the older tricyclic antidepressants and monoamine oxidase inhibitors while avoiding:

- a. Their high potential for abuse
- b. Their need to be injected
- c. Their intolerable side effects
- d. Their short shelf life

6. Dual-action antidepressants may be especially more effective than single-action antidepressants in treating the somatic symptoms that frequently occur in depression.

- a. True
- b. False

- 7. According to Trivedi, in the primary care setting, a high percentage of patients with depression present exclusively with physical symptoms.**
- True
 - False
- 8. According to Trivedi, residual symptoms, including physical symptoms, _____ the likelihood of relapse.**
- Decrease
 - Eliminate
 - Do not affect
 - Increase
- 9. According to Trivedi, physicians should use _____ as a first-line treatment in patients with depression who present with physical symptoms.**
- Single-action antidepressants
 - Dual-action antidepressants
 - Anticonvulsants
 - Atypical antipsychotics
- 10. According to Savard, a patient with depression is more likely than his or her physician to believe that:**
- The physician recommended that treatment last 6 months or longer
 - The physician warned the patient about antidepressant side effects such as weight gain
 - The patient must endure antidepressant side effects
 - The patient and physician collaborate on treatment decisions
- 11. According to Savard, continuation therapy that lasts for _____ after symptoms are resolved is required for patients who have had _____ or more episodes of depression.**
- 4 to 6 weeks; 1
 - 4 to 5 months; 1
 - 4 to 6 weeks; 3
 - 4 to 5 months; 3
- 12. According to Savard, patients with depression should keep track of their initial and current physical and emotional symptoms, side effects, and quality of life measures because these patients often overestimate their response to treatment.**
- True
 - False

CME REGISTRATION FORM

New Treatments for Depression Characterized by Physical Symptoms

Circle the one correct answer for each question.

- | | |
|------------|-------------|
| 1. a b c d | 7. a b |
| 2. a b c d | 8. a b c d |
| 3. a b c d | 9. a b c d |
| 4. a b c d | 10. a b c d |
| 5. a b c d | 11. a b c d |
| 6. a b | 12. a b |

Print or type

Name _____

Social Security Number _____ - _____ - _____
(for CME credit recording purposes)

Degree _____ Specialty _____

Affiliation _____

Address _____

City, State, Zip _____

Phone () _____

Fax () _____

E-Mail _____

Hospital Private Practice Resident Intern

Deadline for submission

For a credit certificate to be issued, please complete this Registration Form no later than February 28, 2006. Online submissions will receive credit certificates immediately. Faxed or mailed submissions will receive credit certificates within 6 to 8 weeks.

Payment

No payment is necessary as this activity is free.

Please evaluate the effectiveness of this CME activity by answering the following questions.

1. Was the educational content relevant to the stated educational objectives? Yes No
2. Did this activity provide information that is useful in your clinical practice? Yes No
3. Was the format of this activity appropriate for the content being presented? Yes No
4. Did the method of presentation hold your interest and make the material easy to understand? Yes No
5. Achievement of educational objectives:
 - A. Enabled me to recognize the link between depression and physical symptoms such as pain. Yes No
 - B. Enabled me to communicate about depression and its treatment with patients when they present with mysterious physical symptoms. Yes No
 - C. Enabled me to describe antidepressant mechanisms of action that may be effective for the treatment of depression and physical symptoms. Yes No
6. Did this CME activity provide a balanced, scientifically rigorous presentation of therapeutic options related to the topic, without commercial bias? Yes No
7. Does the information you received from this CME activity confirm the way you presently manage your patients? Yes No
8. Does the information you received from this CME activity change the way you will manage your patients in the future? Yes No
9. Please offer comments and/or suggested topics for future CME activities.

10. How much time did you spend completing this CME activity?

11. Do you have convenient access to the Internet? Yes No

SEND THIS PAGE TO:

CME INSTITUTE • PHYSICIANS POSTGRADUATE PRESS, INC. • P.O. BOX 752870 • MEMPHIS, TN 38175-2870

YOU MAY FAX THIS PAGE TO: CME INSTITUTE AT 901-751-3444

QUESTIONS? CALL 1-800-489-1001, EXT. 8

WWW.PSYCHIATRIST.COM